# Q3-2026 Kickoff Meeting Minutes (July 1, 2026)
## Executive Launch & Operational Alignment

**Meeting Date:** July 1, 2026  
**Time:** 10:00 AM UTC (1 hour)  
**Attendees:** CEO, CFO, CTO, Compliance Officer (Timothy H.), Engineering Lead, Platform Engineering Lead  
**Status:** ✅ APPROVED — All 5 initiatives officially launched

---

## Agenda & Outcomes

### 1. Q3-2026 Strategic Overview (10 min)

**Presenter:** Timothy Hartzog, Compliance Officer

**Q2-2026 Closeout Results:**
- Compliance score: 88.8/100 (target 87.0) ✅
- All 6 initiatives completed on time or early ✅
- Resource consumption: 98/148 hours (33.8% under budget) ✅
- Zero critical issues; 100% stakeholder approval ✅

**Q3-2026 Strategic Objectives:**
1. **Risk Management (Q3-1):** Establish ISO 14971 FMEA baseline with 18–25 hazard modes
2. **EHR Integration (Q3-2):** Define FHIR US Core 6.1 bidirectional mapping for clinical deployment
3. **Observability (Q3-3):** Deploy persistent trace storage (Grafana Tempo) for production visibility
4. **FDA Readiness (Q3-4):** Comprehensive assessment culminating in GO/NO-GO decision (Aug 21)
5. **Dependency Audit (Q3-5):** Classify all dependencies; close supply chain risk gap

**Q3 Target:** 89/100 compliance score by September 30

**Critical Success Factor:** August 21 FDA decision vote (determines Years 3–5 strategic direction)

---

### 2. Initiative Deep-Dives (20 min)

#### Initiative Q3-1: ISO 14971 FMEA Formalization (4 min)

**Owner:** Timothy Hartzog (Compliance Officer)  
**Duration:** 4 weeks (Jul 1–28)  
**Effort:** ~10 hours

**Scope:**
- Identify 18–25 hazard modes across clinical repos (PedNeoSim.jl, pediatric-cds)
- Assign risk scores (severity, occurrence, detectability)
- Define mitigation strategies for high-risk modes
- Quarterly review cycle operationalized

**Key Milestones:**
- Jul 8: Risk analysis workshop (2 hours, all stakeholders)
- Jul 15: FMEA 50% documented
- Jul 28: FMEA baseline frozen (input to Q3-4 FDA assessment)

**Resources:**
- Compliance Officer: 10 hours
- Clinical Advisor: 2 hours (workshop + review)
- Engineering: 1 hour (technical context)

**Dependencies:** None (parallel execution)

---

#### Initiative Q3-2: EHR Integration Framework (4 min)

**Owner:** Engineering Team Lead  
**Duration:** 6 weeks (Jul 1 – Aug 15)  
**Effort:** ~22 hours

**Scope:**
- FHIR US Core 6.1 bidirectional mapping (5+ resource types)
- Data transformation layer implementation
- 10+ integration validation tests
- Sandbox testing (Epic + Cerner)
- OAuth 2.0 / SMART on FHIR compliance

**Key Milestones:**
- Jul 2: FHIR mapping specification kickoff
- Jul 15: Mapping specification draft complete
- Jul 22: Implementation phase starts
- Aug 1: Sandbox testing in progress
- Aug 15: Integration tests 80%+ complete

**Resources:**
- Engineering Team: 2 engineers + 1 DevOps (22 hours total)
- Clinical Product Manager: 2 hours (requirements)
- Epic/Cerner vendor support (as-needed)

**Dependencies:** Sandbox environment (ready Jul 1) ✅

---

#### Initiative Q3-3: Advanced Observability Phase 2 (4 min)

**Owner:** Platform Engineering Lead  
**Duration:** 5 weeks (Jul 8 – Aug 19)  
**Effort:** ~18 hours

**Scope:**
- Deploy Grafana Tempo (persistent 30+ day trace retention)
- Service mesh sidecar instrumentation
- Service dependency graph dashboard
- Distributed trace detail dashboards
- Sample-based tracing (100% errors, 1% success, 10% high-latency)

**Key Milestones:**
- Jul 8: Tempo deployment begins
- Jul 15: Tempo deployed; instrumentation planning
- Jul 22: Instrumentation phase 1 complete
- Aug 1: Dashboards prototyping
- Aug 19: Production deployment complete

**Resources:**
- Platform Engineering: 2 engineers (18 hours)
- Infrastructure: Blue-green deployment support
- Database team: Replica monitoring for traces

**Dependencies:** Tempo infrastructure (scheduled Jul 8) ✅

---

#### Initiative Q3-4: FDA Premarket Readiness Assessment (4 min)

**Owner:** Timothy Hartzog (Compliance Officer)  
**Duration:** 3 weeks (Aug 1–21)  
**Effort:** ~12 hours (+ 4 hours executive decision)

**Scope:**
- Technical review (IEC 62304 ≥95%, SBOM/VEX, provenance, cybersecurity SSDF v1.1, 21 CFR Part 11)
- Regulatory alignment (device classification, QMS ISO 13485, labeling)
- Business case (2.5+ FTE resource commitment for premarket pathway)
- GO/NO-GO decision vote

**Key Milestones:**
- Jul 1–15: Technical readiness phase 1 (IEC 62304)
- Jul 15–Aug 1: Technical readiness phase 2 (SBOM/VEX, provenance)
- Aug 1–10: Cybersecurity assessment (SSDF v1.1)
- Aug 10–15: Regulatory + legal review
- Aug 15–20: Final business case
- Aug 21, 2 PM UTC: **CRITICAL DECISION VOTE**

**GO Outcome:**
- Assemble premarket package (510(k) or PMA)
- Engage FDA regulatory counsel
- Q4 2026 submission target
- Year 3: FDA regulatory pathway

**NO-GO Outcome:**
- Pivot to TEFCA/QHIN non-device model
- Healthcare IT expansion without device classification
- Year 3: Platform expansion

**Resources:**
- Compliance Officer: 12 hours technical assessment
- Executive committee: 4 hours decision vote (0.5 hr × 4 people)
- External: FDA regulatory counsel (if GO) — budget $15–20K

**Dependencies:** FMEA baseline (input from Q3-1, due Jul 28) ✅

---

#### Initiative Q3-5: Third-Party Dependency Audit (4 min)

**Owner:** Timothy Hartzog (Compliance Officer)  
**Duration:** 2 weeks (Sep 1–14)  
**Effort:** ~8 hours

**Scope:**
- Inventory all dependencies (PedNeoSim.jl, pediatric-cds, audit-service)
- Classify each (Tier 1: Approved BAA, Tier 2: Requires-Review, Tier 3: Prohibited)
- Risk assess high-risk packages (zero-days, unmaintained)
- Dependency policy published (policies/dependencies.md)
- Remediation plan for non-compliant dependencies

**Key Milestones:**
- Sep 1: Dependency audit begins (post-FDA decision)
- Sep 7: Inventory 100% complete; classification 50%
- Sep 14: Classification + risk assessment complete; policy published

**Resources:**
- Compliance Officer: 8 hours
- Engineering: 2 hours (technical dependency context)
- Security team: 1 hour (vulnerability assessment)

**Dependencies:** Aug 21 FDA decision (establishes priority context) ✅

---

### 3. August 21 FDA Decision Preparation (10 min)

**Presenter:** Timothy Hartzog, Compliance Officer

**Decision Date Confirmed:** August 21, 2026 at 2:00 PM UTC

**Decision Committee:**
- CEO (strategic approval authority)
- CFO (resource/budget approval)
- CTO (technical readiness verification)
- Compliance Officer (regulatory assessment + recommendation)

**Assessment Components:**
1. **Technical Readiness** (Compliance Officer)
   - IEC 62304 traceability ≥95% ✅ (current: 100%)
   - SBOM/VEX generation complete ✅ (automated in CI)
   - SLSA v1 provenance for all releases ✅ (Q2 backfill done)
   - Cybersecurity assessment (NIST SP 800-218 SSDF v1.1)
   - 21 CFR Part 11 compliance verification

2. **Regulatory & Legal** (External counsel + Compliance Officer)
   - Device classification determination (510(k) vs. PMA likely)
   - QMS ISO 13485 readiness assessment
   - Clinical labeling requirements
   - Post-market surveillance plan

3. **Business Case** (CEO, CFO)
   - Resource commitment: 2.5+ FTE for premarket pathway
   - Timeline: Q4 2026 submission, Year 2–3 regulatory cycle
   - Budget: FDA consultant + legal fees (est. $50–100K)
   - ROI: Market timing, competitive positioning, clinical impact

**GO Criteria (ALL must be met):**
- ✅ IEC 62304 traceability ≥95%
- ✅ Compliance score ≥87/100
- ✅ Cybersecurity assessment passed
- ✅ Legal sign-off (no blockers)
- ✅ 2.5+ FTE resource commitment secured

**Decision Output:**
- Formal GO/NO-GO vote
- Year 3 roadmap conditional on decision
- Team alignment and next steps

**Timeline Confirmation:**
- Jul 1–Aug 10: Assessment work in progress
- Aug 10–15: Pre-decision briefing and final business case
- Aug 15–20: Executive alignment and Q&A
- Aug 21: Formal decision vote

---

### 4. Q&A & Alignment (10 min)

**CEO Question:** "What's the resource impact if we GO with FDA pathway?"

**CFO Response:** "2.5+ FTE for 18–24 months. Budget estimate: $50–100K for external counsel + legal. Can be absorbed into Year 3 operating budget. Year 4+ royalties/licensing revenue offsets cost."

**CTO Question:** "What's our technical readiness gap, if any?"

**Compliance Officer Response:** "Current readiness: 100% IEC 62304 (Phase 1–2 complete), 95% SLSA provenance (backfill done), 85% code quality (scorecard remediation done). Gap: Cybersecurity SSDF v1.1 assessment (in progress Jul 1–Aug 10); expected pass based on current posture."

**Clinical Advisor Question:** "How does FDA decision impact product roadmap?"

**CEO Response:** "Device pathway: FDA submission Q1 2027; focus shifts to regulatory compliance and post-market surveillance. Non-device pathway: Focus shifts to multi-vendor EHR integration and healthcare IT platform expansion. Both paths are viable; decision based on market opportunity and risk tolerance."

---

## Formal Approvals & Authorizations

**All attendees confirmed and approved:**

- [x] **CEO:** Q3-2026 execution approved; 2.5+ FTE resource commitment authority confirmed
- [x] **CFO:** Budget allocation approved ($100K+ for external counsel if GO on Aug 21); resource reallocation authority confirmed
- [x] **CTO:** Technical readiness assessment framework approved; infrastructure support confirmed
- [x] **Compliance Officer:** Q3 initiative execution authority confirmed; FMEA workshop scheduled Jul 8
- [x] **Engineering Lead:** EHR Integration initiative kickoff confirmed for Jul 2
- [x] **Platform Eng Lead:** Tempo deployment scheduled Jul 8; resource allocation confirmed

**Formal Declaration:**

> All 5 Q3-2026 initiatives are officially LAUNCHED and APPROVED for execution effective July 1, 2026.  
> Compliance score target: 89/100 by September 30, 2026.  
> Critical decision date: August 21, 2026 (FDA GO/NO-GO vote).  
> Year 3 roadmap conditional on August 21 outcome.

---

## Next Steps (By Initiative)

### Immediate (Jul 1–2)

1. **All Teams:** Review respective initiative plans; confirm timeline understanding
2. **Engineering Team:** EHR Integration kickoff scheduled Jul 2, 10 AM UTC
3. **Compliance Officer:** Final prep for FMEA workshop (Jul 8)
4. **Platform Engineering:** Tempo deployment preparation begins

### Week 1 Checkpoints (Jul 8)

1. **FMEA Workshop:** Risk analysis completed (2 hours)
2. **EHR Mapping:** Specification draft progressing
3. **Tempo Deployment:** Scheduled to go live
4. **FDA Assessment:** Technical review phase 1 started
5. **Dependency Audit:** Planning stage (starts Sep 1 post-decision)

### Midpoint Checkpoints (Jul 15, Jul 22, Aug 1)

- Verify all 5 initiatives on track
- Address any blockers
- Confirm Aug 21 decision readiness

---

## Communication Plan

**Status Updates:**
- Weekly standup: Mondays 3 PM UTC (15 min; all initiative leads)
- Bi-weekly executive review: Every other Thursday 4 PM UTC (30 min; steering committee)
- Slack channels:
  - #q3-2026-initiatives (all teams)
  - #compliance-q3 (Q3-1, Q3-4, Q3-5 team)
  - #observability-q3 (Q3-3 team)
  - #ehr-integration-q3 (Q3-2 team)

**Critical Escalation Path:**
1. Initiative lead → Team lead (daily if needed)
2. Team lead → CTO or Compliance Officer (weekly)
3. CTO or Compliance Officer → Executive steering committee (escalation items only)

---

## Conclusion

Q3-2026 execution is officially launched with full executive approval and stakeholder alignment. All infrastructure is ready, resources are committed, and risk mitigation is in place. The organization is positioned to achieve the 89/100 compliance target and make a critical strategic decision on August 21 regarding the FDA device pathway.

**Status: ✅ LAUNCHED & APPROVED**

All 5 initiatives are executing as of July 1, 2026.

---

**Meeting Recorded By:** Timothy Hartzog, Compliance Officer  
**Approved By:** CEO, CFO, CTO  
**Date:** July 1, 2026

